About us
Who We Are
Eukarion, Inc. is a privately held biopharmaceutical company dedicated to advancing innovative therapies for aging and age-related diseases. Since our founding in 1991, we have focused on targeting intracellular mechanisms to develop novel treatments that address some of the most challenging medical conditions. Headquartered in Bedford, MA, we operate at the intersection of biotechnology, drug discovery, and translational medicine, working closely with academic and industry partners to bring cutting-edge research into real-world applications.
What We Do
At Eukarion, we develop proprietary therapeutic agents that combat diseases at the cellular level. Our research is centered on two breakthrough approaches:
- Synthetic Catalytic Scavengers (SCS): A novel class of molecules designed to eliminate harmful reactive oxygen species, which contribute to neurodegenerative, cardiovascular, and autoimmune diseases.
- Lipoclonal® Antibody Technology: A revolutionary method that enables therapeutic antibodies to enter cells and target intracellular disease-related proteins.